Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Mitochondrial health is the foundational research domain for Urolithin A. The compound was first identified as a mitophagy activator in preclinical studies and all subsequent human trials have included mitochondrial biomarkers as key endpoints. This page summarizes the evidence for Urolithin A's effects on mitochondrial function — from the landmark preclinical data through human biomarker outcomes. Mitochondrial dysfunction is recognized as one of the 12 hallmarks of aging (López-Otín et al., Cell, 2023), which provides the scientific rationale for studying compounds that improve mitochondrial quality control. However, biomarker improvements do not automatically translate to clinically meaningful health outcomes.
Why Everything You've Tried for Energy Has Failed
Because none of it reached your mitochondria. Vitamins, adaptogens, superfoods — none of them address the core mechanism. Until now.
Detailed Evidence
PRECLINICAL FOUNDATION: NATURE MEDICINE 2016 The landmark study by Ryu et al. (2016) demonstrated that Urolithin A: (1) induced mitophagy in C. elegans muscle cells, (2) extended C. elegans lifespan by 45%, (3) improved running endurance in aged mice by 42%, and (4) enhanced muscle mitochondrial content and function in rodent models. These findings established the PINK1/Parkin mitophagy pathway as UA's primary mechanism. FIRST HUMAN TRIAL: NATURE METABOLISM 2019 (ANDREUX ET AL.) Design: Randomized, double-blind, placebo-controlled. N=60 healthy elderly participants. Doses: 250 mg, 500 mg, 1000 mg, 2000 mg/day for 28 days. Mitochondrial biomarker results: (1) Plasma acylcarnitines — markers of mitochondrial fatty acid oxidation — decreased in a dose-dependent manner, with significant changes at 500 mg and 1000 mg. (2) Skeletal muscle biopsies (subset of participants) showed molecular signatures of mitophagy activation at the 500 mg and 1000 mg doses, including upregulation of mitophagy-related gene expression. (3) Mitochondrial DNA-to-nuclear DNA ratios showed trends toward improvement. CONFIRMATION IN 4-MONTH TRIALS Both the Liu 2022 (JAMA Network Open) and Singh 2022 (Cell Reports Medicine) trials confirmed sustained improvements in plasma acylcarnitine profiles over 4 months of supplementation at 500–1000 mg/day. These biomarker changes correlated with the functional muscle endurance improvements observed in both trials. BIOMARKERS MEASURED ACROSS TRIALS Key mitochondrial biomarkers measured include: (1) Plasma acylcarnitines — particularly long-chain species (C14, C16, C18) indicating mitochondrial β-oxidation capacity. (2) Plasma ceramides — lipid markers associated with mitochondrial stress. (3) Mitochondrial DNA-to-nuclear DNA ratio in blood cells. (4) Skeletal muscle gene expression for PINK1, Parkin, LC3, and other autophagy/mitophagy markers. (5) C-reactive protein (CRP) as an indirect marker of mitochondrial-driven inflammation. CARDIOVASCULAR MITOCHONDRIAL DATA A 2025 Nature Communications study (Denk et al.) provided preclinical evidence for cardioprotective effects through mitochondrial quality enhancement. A sub-analysis of human data showed improvements in cardiovascular biomarkers, though this remains primarily a preclinical finding.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The Clock Is Ticking Inside Every Cell
Every day without mitochondrial support is a day your cells accumulate more damage, produce less energy, and age faster. The choice is yours.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Does Urolithin A improve mitochondrial function?
Yes. All human trials show improvements in plasma acylcarnitine profiles (markers of mitochondrial fatty acid oxidation) and muscle biopsy data shows molecular signatures of mitophagy activation at 500–1000 mg doses.
What mitochondrial biomarkers does Urolithin A improve?
Plasma acylcarnitines (particularly long-chain C14, C16, C18), plasma ceramides, mitochondrial DNA-to-nuclear DNA ratio, and skeletal muscle gene expression for PINK1, Parkin, LC3, and other mitophagy markers.
How does Urolithin A activate mitophagy?
UA activates the PINK1/Parkin mitophagy pathway — the process by which cells identify and clear damaged mitochondria. This was established in the 2016 Nature Medicine landmark study and confirmed in human muscle biopsies.
What did the landmark 2016 Urolithin A study show?
Ryu et al. 2016 (Nature Medicine) showed UA induced mitophagy in C. elegans, extended lifespan by 45%, improved aged mouse running endurance by 42%, and enhanced muscle mitochondrial content. This established the scientific rationale for human trials.
How quickly do mitochondrial biomarkers respond to Urolithin A?
Dose-dependent plasma acylcarnitine changes were detected within 28 days in the Andreux 2019 trial at 500 mg and 1000 mg doses. Sustained improvements were confirmed over 4 months in subsequent trials.
Did muscle biopsies confirm mitophagy activation in humans?
Yes. A subset of participants in the Andreux 2019 trial underwent skeletal muscle biopsies showing molecular signatures of mitophagy activation (PINK1/Parkin pathway upregulation) at 500–1000 mg doses.
What are acylcarnitines and why do they matter?
Acylcarnitines are markers of mitochondrial fatty acid oxidation. Elevated levels indicate impaired β-oxidation. Their decrease with UA supplementation suggests improved mitochondrial function.
Is mitochondrial dysfunction really a hallmark of aging?
Yes. López-Otín et al. (Cell, 2023) identified mitochondrial dysfunction as one of the 12 hallmarks of aging. This provides the scientific rationale for studying mitophagy-activating interventions.
Does Urolithin A affect mitochondrial DNA?
Mitochondrial DNA-to-nuclear DNA ratios showed trends toward improvement in the Andreux 2019 trial. Direct measurement of mtDNA quality in humans is limited.
Can you directly measure mitophagy in living humans?
Direct tissue-level mitophagy measurement in living humans is extremely limited. Evidence comes from small muscle biopsy subsets and indirect biomarker changes, not direct real-time measurement.
Does exercise also improve mitochondrial biomarkers?
Yes. Exercise is a potent activator of mitophagy and mitochondrial biogenesis. No head-to-head comparison between UA and exercise for mitochondrial biomarkers has been conducted.
Are mitochondrial biomarker improvements clinically meaningful?
Biomarker improvements are indirect measures. Acylcarnitine reductions are surrogate markers, not direct health outcomes. Whether they translate to clinically meaningful benefits requires further study.
What dose optimally improves mitochondrial markers?
Dose-dependent changes were detected at 500 mg and 1000 mg. The 2000 mg dose did not show additional benefit over 1000 mg. 500–1000 mg/day appears to be the effective range.
Does Urolithin A affect cardiac mitochondria?
The Denk 2025 Nature Communications study demonstrated cardioprotective effects through mitochondrial quality enhancement in preclinical models. Human cardiovascular data is a sub-analysis and remains early-stage.
How long do mitochondrial improvements last?
Sustained improvements were confirmed over 4 months. Long-term effects of chronic mitophagy activation are not characterized in humans. No trial longer than 4 months has been published.
Key Research Facts
UA treatment extended C. elegans lifespan by 45% and improved aged mouse running endurance by 42% in the 2016 Nature Medicine landmark study.
Strong EvidenceRyu et al., Nature Medicine — doi:10.1038/nm.4132
The first human trial detected dose-dependent plasma acylcarnitine changes at 500 mg and 1000 mg doses within 28 days.
Strong EvidenceAndreux et al., Nature Metabolism — doi:10.1038/s42255-019-0073-4
Skeletal muscle biopsies showed molecular signatures of mitophagy activation (PINK1/Parkin pathway upregulation) at 500–1000 mg doses.
Moderate EvidenceAndreux et al., Nature Metabolism — doi:10.1038/s42255-019-0073-4
Sustained acylcarnitine improvements were confirmed over 4 months in both the Liu 2022 and Singh 2022 trials.
Strong EvidenceLiu et al., 2022; Singh et al., 2022 — doi:10.1001/jamanetworkopen.2021.44279
Mitochondrial dysfunction is one of the 12 hallmarks of aging, providing the scientific rationale for mitophagy-activating interventions.
Strong EvidenceLópez-Otín et al., Cell — doi:10.1016/j.cell.2022.11.001
Long-chain acylcarnitines (C14, C16, C18) — markers of impaired mitochondrial β-oxidation — consistently decrease with UA supplementation.
Strong EvidenceAndreux et al., 2019; Singh et al., 2022 — doi:10.1038/s42255-019-0073-4
A 2025 Nature Communications study demonstrated cardioprotective effects through mitochondrial quality enhancement in preclinical models.
Emerging EvidenceDenk et al., Nature Communications — doi:10.1038/s41467-025-57067-3
The degree of mitophagy activation from oral supplementation in humans is measured indirectly — direct tissue-level evidence is limited to small biopsy subsets.
Moderate EvidenceAndreux et al., Nature Metabolism — doi:10.1038/s42255-019-0073-4
The 2000 mg dose tested in the 28-day safety trial did not show additional mitochondrial biomarker benefit over 1000 mg.
Moderate EvidenceAndreux et al., Nature Metabolism — doi:10.1038/s42255-019-0073-4
Acylcarnitine improvements correlated with functional muscle endurance gains across multiple trials, supporting a causal mitochondrial mechanism.
Moderate EvidenceLiu et al., 2022; Singh et al., 2022 — doi:10.1001/jamanetworkopen.2021.44279
Citations & External Resources
ClinicalTrials.gov — Search: Urolithin A
FDA GRAS Notice GRN 000833 — Urolithin A
EFSA Novel Food Catalogue — Urolithin A
PubMed — Urolithin A research
Nature Medicine — Ryu et al. 2016 (Landmark Study)
JAMA Network Open — Liu et al. 2022 (Muscle Endurance RCT)
Cell — López-Otín et al. 2023: Hallmarks of Aging Update
Nature Communications — Denk et al. 2025 (Cardioprotection)
Nature Metabolism — Andreux et al. 2019 (First Human Mitochondrial Data)
Proof That Cellular Science Has Outpaced the Supplement Industry
While most brands still sell yesterday's vitamins, science has moved to mitophagy, senolytics, and NAD+ pathways. Catch up.
Related Reading
Urolithin A: How It Works (Mitophagy Mechanisms)
Urolithin A Benefits: Clinical Evidence
Urolithin A & Healthy Aging: Research Context
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026